Business, energy, technology, markets and global industry news from Business News Today

European Society of Cardiology

PharmaDeviceNews European Society of Cardiology
Representative image: Laboratory monitoring of gene-editing and lipid data as CRISPR Therapeutics reports one-year CTX310 results showing durable ANGPTL3, triglyceride and LDL cholesterol reductions after a single in vivo CRISPR treatment.
Pharma & Biotech

CTX310 delivers one-year lipid reductions as CRISPR Therapeutics advances in vivo cardiovascular editing

CTX310 sustains deep ANGPTL3, LDL and triglyceride reductions for one year after one infusion. See what the data mean for CRISPR Therapeutics.

Read More
Representative image: Cardiac imaging and hypertrophic cardiomyopathy assessment as Cytokinetics reports positive Phase 3 ACACIA-HCM results for aficamten, supporting a planned FDA filing in symptomatic non-obstructive HCM.
Pharma & Biotech

Aficamten clears pivotal Phase 3 test in non-obstructive HCM as Cytokinetics prepares FDA filing

Aficamten hits both Phase 3 ACACIA-HCM endpoints as Cytokinetics prepares an FDA filing. See what the results mean for Myqorzo growth.

Read More